Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NRG Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2014-01-01

Employees: 51

Market Cap: -

Website: http://www.nrgoncology.org

Clinical Trials

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Stage II Prostate Adenocarcinoma AJCC v7
Stage I Prostate Adenocarcinoma AJCC v7
Stage III Prostate Adenocarcinoma AJCC v7

Interventions: Drug: Bicalutamide
Drug: Degarelix
Radiation: External Beam Radiation Therapy
Drug: Docetaxel
Drug: Flutamide
Drug: Goserelin
Drug: Goserelin Acetate
Other: Laboratory Biomarker Analysis
Drug: Leuprolide
Drug: Leuprolide Acetate
Drug: Nilutamide

First Posted Date: 2017-03-06

Last Posted Date: 2025-05-09

Lead Sponsor: NRG Oncology

Target Recruit Count: 612

Registration Number: NCT03070886

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 310 locations

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Endometrioid Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Metastatic Endometrioid Adenocarcinoma
Recurrent Uterine Corpus Cancer

Interventions: Drug: Copanlisib
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-04-05

Last Posted Date: 2022-02-15

Lead Sponsor: NRG Oncology

Target Recruit Count: 11

Registration Number: NCT02728258

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 40 locations

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
FIGO Stage III Ovarian Cancer 2014
FIGO Stage IIIA Ovarian Cancer 2014
FIGO Stage IIIA1 Ovarian Cancer
FIGO Stage IIIA2 Ovarian Cancer
FIGO Stage IIIB Ovarian Cancer 2014
FIGO Stage IIIC Ovarian Cancer 2014
FIGO Stage IVA Ovarian Cancer 2014

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Procedure: Therapeutic Conventional Surgery
Drug: Ruxolitinib Phosphate

First Posted Date: 2016-03-18

Last Posted Date: 2025-05-25

Lead Sponsor: NRG Oncology

Target Recruit Count: 147

Registration Number: NCT02713386

Locations: 🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 107 locations

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Limited Stage Small Cell Lung Carcinoma
Extensive Stage Small Cell Lung Carcinoma

Interventions: Radiation: Intensity-Modulated Radiation Therapy
Radiation: Three-Dimensional Conformal Radiation Therapy

First Posted Date: 2015-12-18

Last Posted Date: 2024-07-17

Lead Sponsor: NRG Oncology

Target Recruit Count: 418

Registration Number: NCT02635009

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Lewis and Faye Manderson Cancer Center, Tuscaloosa, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 282 locations

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3

Active, not recruiting

Conditions: Progesterone Receptor Negative
Estrogen Receptor Negative
HER2/Neu Negative
Stage IIA Breast Cancer
Triple-Negative Breast Carcinoma
Breast Adenocarcinoma
Stage IB Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2015-07-02

Last Posted Date: 2024-06-03

Lead Sponsor: NRG Oncology

Target Recruit Count: 782

Registration Number: NCT02488967

Locations: 🇺🇸
Southern Cancer Center PC-Mobile, Mobile, Alabama, United States
🇺🇸
Southern Cancer Center PC-Providence, Mobile, Alabama, United States
🇺🇸
Southern Cancer Center PC-Springhill, Mobile, Alabama, United States

and more 1285 locations

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Lung
Metastatic Malignant Neoplasm in the Lymph Nodes
Metastatic Malignant Neoplasm in the Spine
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Liver

Interventions: Radiation: Stereotactic Body Radiotherapy
Procedure: Surgery

First Posted Date: 2015-02-18

Last Posted Date: 2025-01-16

Lead Sponsor: NRG Oncology

Target Recruit Count: 129

Registration Number: NCT02364557

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States

and more 162 locations

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

Phase 3

Completed

Conditions: Cognitive Impairment
Solid Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Radiation: Whole brain radiation therapy with hippocampal avoidance
Drug: Memantine
Radiation: Whole brain radiation therapy

First Posted Date: 2015-02-10

Last Posted Date: 2025-04-23

Lead Sponsor: NRG Oncology

Target Recruit Count: 518

Registration Number: NCT02360215

Locations: 🇺🇸
Lewis and Faye Manderson Cancer Center, Tuscaloosa, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 217 locations

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

Phase 2

Terminated

Conditions: Stage III Bladder Cancer
Stage IV Bladder Cancer

Interventions: Radiation: Intensity-Modulated Radiation Therapy

First Posted Date: 2014-12-15

Last Posted Date: 2024-11-29

Lead Sponsor: NRG Oncology

Target Recruit Count: 14

Registration Number: NCT02316548

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States

and more 124 locations

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Completed

Conditions: Fallopian Tube Carcinoma
Stage IIIB Uterine Corpus Cancer AJCC v7
Primary Peritoneal Carcinoma
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7
Ovarian Carcinoma
Endometrial Serous Adenocarcinoma
Malignant Female Reproductive System Neoplasm
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IVB Uterine Corpus Cancer AJCC v7

Interventions: Other: Comprehensive Geriatric Assessment
Other: Questionnaire Administration

First Posted Date: 2014-12-11

Last Posted Date: 2021-11-24

Lead Sponsor: NRG Oncology

Target Recruit Count: 190

Registration Number: NCT02315469

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

and more 390 locations

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

Phase 2

Active, not recruiting

Conditions: Stage IVC Oropharyngeal Squamous Cell Carcinoma
Stage III Oropharyngeal Squamous Cell Carcinoma
Stage IVA Oropharyngeal Squamous Cell Carcinoma
Stage IVB Oropharyngeal Squamous Cell Carcinoma
Tongue Carcinoma

Interventions: Radiation: IMRT 5 weeks
Drug: Cisplatin
Radiation: IMRT 6 weeks

First Posted Date: 2014-10-01

Last Posted Date: 2025-02-28

Lead Sponsor: NRG Oncology

Target Recruit Count: 316

Registration Number: NCT02254278

Locations: 🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸
Olathe Health Cancer Center, Olathe, Kansas, United States

and more 219 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy